Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Stock Price Today
Aura AI Summary
Key Stats
- $10.22BMarket Cap
- -Volume
- HealthSector
- $390.3452W High
- $241.7152W Low
- -Typical Hold Time
- $9.97BEnterprise Value
- -Div Yield
- -Trading Activity
Track Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Bio-Rad Laboratories, Inc. Class A Common Stock has traded between a low of $241.71 and a high of $390.34, highlighting its annual price range. Buy and sell Bio-Rad Laboratories, Inc. Class A Common Stock shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Most Recent News
OPEC+ holds oil output steady for October amid Iran war disruptions
OPEC+ decided to keep its oil production unchanged for October, awaiting a full review of member capacities before setting new 2027 quotas. The ongoing Iran war disrupts exports through the Strait of Hormuz, limiting OPEC+'s ability to meet productio...
Nvidia could earn $851B in annual profit by 2029, rivaling the GDP of a major country.
Nvidia is projected to generate approximately $851 billion in annual net income by 2029 if its earnings per share grow at a compounded rate of 64%, far surpassing Saudi Aramco's record profit of $161 billion in 2022. This growth would place Nvidia's ...
Class action lawsuit filed against Unicycive Therapeutics over alleged false statements on manufacturing compliance.
A class action lawsuit has been filed against Unicycive Therapeutics and some of its officers for allegedly making false and misleading statements about the compliance of a third-party manufacturing vendor. The complaint claims Unicycive did not prop...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.